ArticleCell discovery2018
Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration.
Article in Cell discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Cell therapy for retinal degenerative disorders: a systematic review and three-level meta-analysis.Journal of translational medicine · 2024Pooled it
- Immunosuppression in stem cell clinical trials of neural and retinal cell types: A systematic review.PloS one · 2024Pooled it
- Stem Cell-based Treatment Strategies for Degenerative Diseases of the Retina.Current stem cell research & therapy · 2022Pooled it
- Safe CNV removal is crucial for successful hESC-RPE transplantation in wet age-related macular degeneration.Stem cell reports · 2025Trial
- Cellular Products with Anti-Inflammatory Properties for the Treatment of Cartilage Lesions.International journal of molecular sciences · 2026Review
- Advances in retinal pigment epithelium transplantation for age-related macular degeneration: bridging biology to therapeutic frontiers.Stem cell research & therapy · 2026Review
- Review
- Tissue factor and regenerative medicine: shaping cell and extracellular vesicle-based therapeutic approaches.Frontiers in cell and developmental biology · 2026Review
- A New Vision for Ocular Disease: Stem Cell Strategies in Regenerative Ophthalmology.Stem cell reviews and reports · 2026Review
- Retinal Pigment Epithelium Transplantation in Retinal Disease: Clinical Trial Development, Challenges, and Future Directions.Biomolecules · 2025Review
- PD-L1 Promotes Immunological Tolerance and Enhances Visual Protection of hESC-RPE Grafts in Retinal Degeneration.Cell proliferation · 2025Article
- Age-Related Macular Degeneration: Cellular and Molecular Signaling Mechanisms.International journal of molecular sciences · 2025Review
- Delivery of Human iPSC-Derived RPE Cells in Healthy Minipig Retina Results in Interaction Between Photoreceptors and Transplanted Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Innovative approaches to treatment of eye diseases: advances in stem cell therapy use in ophthalmology.International ophthalmology · 2025Review
- Advances in the Study of Age-Related Macular Degeneration Based on Cell or Cell-Biomaterial Scaffolds.Bioengineering (Basel, Switzerland) · 2025Review
- The Programme for Manufacture of hPSC‑Based Products for AMD and PD.Advances in experimental medicine and biology · 2025Review
- Advances in the study of tissue-engineered retinal pigment epithelial cell sheets.Regenerative therapy · 2024Review
- Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells.Communications medicine · 2024Article
- Standardisation is the key to the sustained, rapid and healthy development of stem cell-based therapy.Clinical and translational medicine · 2024Review
- Recent Advances in Alginate-Based Hydrogels for Cell Transplantation Applications.Pharmaceutics · 2024Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem cell therapy may provide a safe and promising treatment for retinal diseases. Wet age-related macular degeneration (wet-AMD) is a leading cause of blindness in China. We developed a clinical-grade human embryonic stem cell (hESC) line, Q-CTS-hESC-2, under xeno-free conditions that differentiated into retinal pigment epithelial cells (Q-CTS-hESC-2-RPE). A clinical trial with three wet-AMD patients was initiated in order to study the safety and tolerance to Q-CTS-hESC-2-RPE cell transplants. The choroidal neovascularization membrane was removed and then a suspension of 1 × 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.